Compare
MaxCyte, Inc. vs OmniAb, Inc. vs NRC Health vs bioAffinity Technologies, Inc.
| Latest fiscal year | MaxCyte, Inc. MXCT | OmniAb, Inc. OABI | NRC Health NRC | bioAffinity Technologies, Inc. BIAF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $33.03M | $18.67M | $137.39M | $6.16M |
| Revenue growth (YoY) | -14.5% | -29.3% | -4.0% | -34.2% |
| Gross margin | 81.2% | n/a | n/a | n/a |
| Operating margin | -157.1% | -369.5% | 16.4% | -171.6% |
| Net margin | -135.1% | -347.0% | 8.4% | -242.0% |
| Net income | -$44.63M | -$64.78M | $11.60M | -$14.91M |
| EPS (Diluted) | -$0.42 | -$0.57 | $50.00 | -$8.66 |
| Operating cash flow | -$34.41M | -$36.45M | $26.45M | -$9.33M |
| Free cash flow | -$36.18M | -$37.02M | $15.74M | -$9.39M |
| Cash & equivalents | $20.07M | $25.52M | $4.14M | $6.45M |
| Total assets | $202.51M | $300.91M | $134.88M | $10.96M |
| Total liabilities | $31.02M | $33.89M | $120.89M | $3.68M |
| Shareholders' equity | $171.49M | $267.03M | $13.99M | $7.28M |
| Return on year-end equity | -26.0% | -24.3% | 82.9% | -204.9% |
| Shares outstanding | 106.79M | 144.31M | 22.64M | 4.50M |
Revenue, most recent five fiscal years
| Fiscal year | MaxCyte, Inc. | OmniAb, Inc. | NRC Health | bioAffinity Technologies, Inc. |
|---|---|---|---|---|
| Latest | $33.03M Ended 2025-12-31 | $18.67M Ended 2025-12-31 | $137.39M Ended 2025-12-31 | $6.16M Ended 2025-12-31 |
| 1 year earlier | $38.63M Ended 2024-12-31 | $26.39M Ended 2024-12-31 | $143.06M Ended 2024-12-31 | $9.36M Ended 2024-12-31 |
| 2 years earlier | $41.29M Ended 2023-12-31 | $34.16M Ended 2023-12-31 | $148.58M Ended 2023-12-31 | $2.53M Ended 2023-12-31 |
| 3 years earlier | $44.26M Ended 2022-12-31 | $59.08M Ended 2022-12-31 | $151.57M Ended 2022-12-31 | $6.90M Ended 2022-12-31 |
| 4 years earlier | $33.89M Ended 2021-12-31 | $34.75M Ended 2021-12-31 | $147.95M Ended 2021-12-31 | n/a |